Human Milk Oligosaccharide 2'-Fucosyllactose Inhibits Ligand Binding to C-Type Lectin DC-SIGN but Not to Langerin

Human milk oligosaccharides (HMOs) and their most abundant component, 2'-Fucosyllactose (2'-FL), are known to be immunomodulatory. Previously, it was shown that HMOs and 2'-FL bind to the C-type lectin receptor DC-SIGN. Here we show, using a ligand-receptor competition assay, that a w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of molecular sciences 2022-11, Vol.23 (23), p.14745
Hauptverfasser: Mukherjee, Reshmi, Somovilla, Victor J, Chiodo, Fabrizio, Bruijns, Sven, Pieters, Roland J, Garssen, Johan, van Kooyk, Yvette, Kraneveld, Aletta D, van Bergenhenegouwen, Jeroen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 23
container_start_page 14745
container_title International journal of molecular sciences
container_volume 23
creator Mukherjee, Reshmi
Somovilla, Victor J
Chiodo, Fabrizio
Bruijns, Sven
Pieters, Roland J
Garssen, Johan
van Kooyk, Yvette
Kraneveld, Aletta D
van Bergenhenegouwen, Jeroen
description Human milk oligosaccharides (HMOs) and their most abundant component, 2'-Fucosyllactose (2'-FL), are known to be immunomodulatory. Previously, it was shown that HMOs and 2'-FL bind to the C-type lectin receptor DC-SIGN. Here we show, using a ligand-receptor competition assay, that a whole mixture of HMOs from pooled human milk (HMOS) and 2'-FL inhibit the binding of the carbohydrate-binding receptor DC-SIGN to its prototypical ligands, fucose and the oligosaccharide Lewis-B, (Le ) in a dose-dependent way. Interestingly, such inhibition by HMOS and 2'-FL was not detected for another C-type lectin, langerin, which is evolutionarily similar to DC-SIGN. The cell-ligand competition assay using DC-SIGN expressing cells confirmed that 2'-FL inhibits the binding of DC-SIGN to Le . Molecular dynamic (MD) simulations show that 2'-FL exists in a preorganized bioactive conformation before binding to DC-SIGN and this conformation is retained after binding to DC-SIGN. Le has more flexible conformations and utilizes two binding modes, which operate one at a time via its two fucoses to bind to DC-SIGN. Our hypothesis is that 2'-FL may have a reduced entropic penalty due to its preorganized state, compared to Le , and it has a lower binding enthalpy, suggesting a better binding to DC-SIGN. Thus, due to the better binding to DC-SIGN, 2'-FL may replace Le from its binding pocket in DC-SIGN. The MD simulations also showed that 2'-FL does not bind to langerin. Our studies confirm 2'-FL as a specific ligand for DC-SIGN and suggest that 2'-FL can replace other DC-SIGN ligands from its binding pocket during the ligand-receptor interactions in possible immunomodulatory processes.
doi_str_mv 10.3390/ijms232314745
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9737664</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2753302978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-4f31cdaa1cb72e8344e30e22f8418f650dfb664e2af9d22d475d7c9c70acc87c3</originalsourceid><addsrcrecordid>eNpdkc1P3DAQxa2qqLsFjr1WlnpoLwHHduLkUommfKwU4ACcLcd2st4m9mI7lfa_x4gPAacZzfz0NG8eAN9ydERIjY7NZgqYYJJTRotPYJlTjDOESvb5Tb8AX0PYIJTAov4CFqSkdZ3mS3B_MU_Cwksz_oPXoxlcEFKuhTdKQ_wzO5ulC7txFDK6oOHKrk1nYoCtGYRV8I-xytgBRgeb7Ha31bDVMhoL_zbZzer8CnZzhFcuPgKtsIP2xh6AvV6MQR8-131wd3Z621xk7fX5qjlpM0nzIma0J7lUQuSyY1hXhFJNkMa4r2he9WWBVN-VJdVY9LXCWFFWKCZryVAyUDFJ9sHvJ93t3E1aSW2jFyPfejMJv-NOGP5-Y82aD-4_rxlhSTkJ_HoW8O5-1iHyyQSp0zOsdnPgmBWEIFyzKqE_PqAbN3ub7CWKVkWBKsoSlT1R0rsQvO5fj8kRfwyTvwsz8d_fOnilX9IjD8ramvI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2748550847</pqid></control><display><type>article</type><title>Human Milk Oligosaccharide 2'-Fucosyllactose Inhibits Ligand Binding to C-Type Lectin DC-SIGN but Not to Langerin</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Mukherjee, Reshmi ; Somovilla, Victor J ; Chiodo, Fabrizio ; Bruijns, Sven ; Pieters, Roland J ; Garssen, Johan ; van Kooyk, Yvette ; Kraneveld, Aletta D ; van Bergenhenegouwen, Jeroen</creator><creatorcontrib>Mukherjee, Reshmi ; Somovilla, Victor J ; Chiodo, Fabrizio ; Bruijns, Sven ; Pieters, Roland J ; Garssen, Johan ; van Kooyk, Yvette ; Kraneveld, Aletta D ; van Bergenhenegouwen, Jeroen</creatorcontrib><description>Human milk oligosaccharides (HMOs) and their most abundant component, 2'-Fucosyllactose (2'-FL), are known to be immunomodulatory. Previously, it was shown that HMOs and 2'-FL bind to the C-type lectin receptor DC-SIGN. Here we show, using a ligand-receptor competition assay, that a whole mixture of HMOs from pooled human milk (HMOS) and 2'-FL inhibit the binding of the carbohydrate-binding receptor DC-SIGN to its prototypical ligands, fucose and the oligosaccharide Lewis-B, (Le ) in a dose-dependent way. Interestingly, such inhibition by HMOS and 2'-FL was not detected for another C-type lectin, langerin, which is evolutionarily similar to DC-SIGN. The cell-ligand competition assay using DC-SIGN expressing cells confirmed that 2'-FL inhibits the binding of DC-SIGN to Le . Molecular dynamic (MD) simulations show that 2'-FL exists in a preorganized bioactive conformation before binding to DC-SIGN and this conformation is retained after binding to DC-SIGN. Le has more flexible conformations and utilizes two binding modes, which operate one at a time via its two fucoses to bind to DC-SIGN. Our hypothesis is that 2'-FL may have a reduced entropic penalty due to its preorganized state, compared to Le , and it has a lower binding enthalpy, suggesting a better binding to DC-SIGN. Thus, due to the better binding to DC-SIGN, 2'-FL may replace Le from its binding pocket in DC-SIGN. The MD simulations also showed that 2'-FL does not bind to langerin. Our studies confirm 2'-FL as a specific ligand for DC-SIGN and suggest that 2'-FL can replace other DC-SIGN ligands from its binding pocket during the ligand-receptor interactions in possible immunomodulatory processes.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms232314745</identifier><identifier>PMID: 36499067</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Binding ; Breast milk ; Carbohydrates ; Competition ; Conformation ; DC-SIGN protein ; Dendritic cells ; Fucose - analysis ; Humans ; Hydrogen bonds ; Immunomodulation ; Lactose ; Lectins, C-Type - metabolism ; Ligands ; Milk ; Milk, Human - metabolism ; Molecular dynamics ; Oligosaccharides ; Receptors, Cell Surface - metabolism ; Simulation ; Trisaccharides - pharmacology</subject><ispartof>International journal of molecular sciences, 2022-11, Vol.23 (23), p.14745</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-4f31cdaa1cb72e8344e30e22f8418f650dfb664e2af9d22d475d7c9c70acc87c3</citedby><cites>FETCH-LOGICAL-c415t-4f31cdaa1cb72e8344e30e22f8418f650dfb664e2af9d22d475d7c9c70acc87c3</cites><orcidid>0000-0001-9819-383X ; 0000-0001-8517-4904 ; 0000-0003-3619-9982 ; 0000-0002-8678-9182 ; 0000-0003-4723-3584 ; 0000-0002-6098-5281</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737664/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737664/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36499067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mukherjee, Reshmi</creatorcontrib><creatorcontrib>Somovilla, Victor J</creatorcontrib><creatorcontrib>Chiodo, Fabrizio</creatorcontrib><creatorcontrib>Bruijns, Sven</creatorcontrib><creatorcontrib>Pieters, Roland J</creatorcontrib><creatorcontrib>Garssen, Johan</creatorcontrib><creatorcontrib>van Kooyk, Yvette</creatorcontrib><creatorcontrib>Kraneveld, Aletta D</creatorcontrib><creatorcontrib>van Bergenhenegouwen, Jeroen</creatorcontrib><title>Human Milk Oligosaccharide 2'-Fucosyllactose Inhibits Ligand Binding to C-Type Lectin DC-SIGN but Not to Langerin</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Human milk oligosaccharides (HMOs) and their most abundant component, 2'-Fucosyllactose (2'-FL), are known to be immunomodulatory. Previously, it was shown that HMOs and 2'-FL bind to the C-type lectin receptor DC-SIGN. Here we show, using a ligand-receptor competition assay, that a whole mixture of HMOs from pooled human milk (HMOS) and 2'-FL inhibit the binding of the carbohydrate-binding receptor DC-SIGN to its prototypical ligands, fucose and the oligosaccharide Lewis-B, (Le ) in a dose-dependent way. Interestingly, such inhibition by HMOS and 2'-FL was not detected for another C-type lectin, langerin, which is evolutionarily similar to DC-SIGN. The cell-ligand competition assay using DC-SIGN expressing cells confirmed that 2'-FL inhibits the binding of DC-SIGN to Le . Molecular dynamic (MD) simulations show that 2'-FL exists in a preorganized bioactive conformation before binding to DC-SIGN and this conformation is retained after binding to DC-SIGN. Le has more flexible conformations and utilizes two binding modes, which operate one at a time via its two fucoses to bind to DC-SIGN. Our hypothesis is that 2'-FL may have a reduced entropic penalty due to its preorganized state, compared to Le , and it has a lower binding enthalpy, suggesting a better binding to DC-SIGN. Thus, due to the better binding to DC-SIGN, 2'-FL may replace Le from its binding pocket in DC-SIGN. The MD simulations also showed that 2'-FL does not bind to langerin. Our studies confirm 2'-FL as a specific ligand for DC-SIGN and suggest that 2'-FL can replace other DC-SIGN ligands from its binding pocket during the ligand-receptor interactions in possible immunomodulatory processes.</description><subject>Antigens</subject><subject>Binding</subject><subject>Breast milk</subject><subject>Carbohydrates</subject><subject>Competition</subject><subject>Conformation</subject><subject>DC-SIGN protein</subject><subject>Dendritic cells</subject><subject>Fucose - analysis</subject><subject>Humans</subject><subject>Hydrogen bonds</subject><subject>Immunomodulation</subject><subject>Lactose</subject><subject>Lectins, C-Type - metabolism</subject><subject>Ligands</subject><subject>Milk</subject><subject>Milk, Human - metabolism</subject><subject>Molecular dynamics</subject><subject>Oligosaccharides</subject><subject>Receptors, Cell Surface - metabolism</subject><subject>Simulation</subject><subject>Trisaccharides - pharmacology</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1P3DAQxa2qqLsFjr1WlnpoLwHHduLkUommfKwU4ACcLcd2st4m9mI7lfa_x4gPAacZzfz0NG8eAN9ydERIjY7NZgqYYJJTRotPYJlTjDOESvb5Tb8AX0PYIJTAov4CFqSkdZ3mS3B_MU_Cwksz_oPXoxlcEFKuhTdKQ_wzO5ulC7txFDK6oOHKrk1nYoCtGYRV8I-xytgBRgeb7Ha31bDVMhoL_zbZzer8CnZzhFcuPgKtsIP2xh6AvV6MQR8-131wd3Z621xk7fX5qjlpM0nzIma0J7lUQuSyY1hXhFJNkMa4r2he9WWBVN-VJdVY9LXCWFFWKCZryVAyUDFJ9sHvJ93t3E1aSW2jFyPfejMJv-NOGP5-Y82aD-4_rxlhSTkJ_HoW8O5-1iHyyQSp0zOsdnPgmBWEIFyzKqE_PqAbN3ub7CWKVkWBKsoSlT1R0rsQvO5fj8kRfwyTvwsz8d_fOnilX9IjD8ramvI</recordid><startdate>20221125</startdate><enddate>20221125</enddate><creator>Mukherjee, Reshmi</creator><creator>Somovilla, Victor J</creator><creator>Chiodo, Fabrizio</creator><creator>Bruijns, Sven</creator><creator>Pieters, Roland J</creator><creator>Garssen, Johan</creator><creator>van Kooyk, Yvette</creator><creator>Kraneveld, Aletta D</creator><creator>van Bergenhenegouwen, Jeroen</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9819-383X</orcidid><orcidid>https://orcid.org/0000-0001-8517-4904</orcidid><orcidid>https://orcid.org/0000-0003-3619-9982</orcidid><orcidid>https://orcid.org/0000-0002-8678-9182</orcidid><orcidid>https://orcid.org/0000-0003-4723-3584</orcidid><orcidid>https://orcid.org/0000-0002-6098-5281</orcidid></search><sort><creationdate>20221125</creationdate><title>Human Milk Oligosaccharide 2'-Fucosyllactose Inhibits Ligand Binding to C-Type Lectin DC-SIGN but Not to Langerin</title><author>Mukherjee, Reshmi ; Somovilla, Victor J ; Chiodo, Fabrizio ; Bruijns, Sven ; Pieters, Roland J ; Garssen, Johan ; van Kooyk, Yvette ; Kraneveld, Aletta D ; van Bergenhenegouwen, Jeroen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-4f31cdaa1cb72e8344e30e22f8418f650dfb664e2af9d22d475d7c9c70acc87c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Binding</topic><topic>Breast milk</topic><topic>Carbohydrates</topic><topic>Competition</topic><topic>Conformation</topic><topic>DC-SIGN protein</topic><topic>Dendritic cells</topic><topic>Fucose - analysis</topic><topic>Humans</topic><topic>Hydrogen bonds</topic><topic>Immunomodulation</topic><topic>Lactose</topic><topic>Lectins, C-Type - metabolism</topic><topic>Ligands</topic><topic>Milk</topic><topic>Milk, Human - metabolism</topic><topic>Molecular dynamics</topic><topic>Oligosaccharides</topic><topic>Receptors, Cell Surface - metabolism</topic><topic>Simulation</topic><topic>Trisaccharides - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mukherjee, Reshmi</creatorcontrib><creatorcontrib>Somovilla, Victor J</creatorcontrib><creatorcontrib>Chiodo, Fabrizio</creatorcontrib><creatorcontrib>Bruijns, Sven</creatorcontrib><creatorcontrib>Pieters, Roland J</creatorcontrib><creatorcontrib>Garssen, Johan</creatorcontrib><creatorcontrib>van Kooyk, Yvette</creatorcontrib><creatorcontrib>Kraneveld, Aletta D</creatorcontrib><creatorcontrib>van Bergenhenegouwen, Jeroen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mukherjee, Reshmi</au><au>Somovilla, Victor J</au><au>Chiodo, Fabrizio</au><au>Bruijns, Sven</au><au>Pieters, Roland J</au><au>Garssen, Johan</au><au>van Kooyk, Yvette</au><au>Kraneveld, Aletta D</au><au>van Bergenhenegouwen, Jeroen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human Milk Oligosaccharide 2'-Fucosyllactose Inhibits Ligand Binding to C-Type Lectin DC-SIGN but Not to Langerin</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2022-11-25</date><risdate>2022</risdate><volume>23</volume><issue>23</issue><spage>14745</spage><pages>14745-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Human milk oligosaccharides (HMOs) and their most abundant component, 2'-Fucosyllactose (2'-FL), are known to be immunomodulatory. Previously, it was shown that HMOs and 2'-FL bind to the C-type lectin receptor DC-SIGN. Here we show, using a ligand-receptor competition assay, that a whole mixture of HMOs from pooled human milk (HMOS) and 2'-FL inhibit the binding of the carbohydrate-binding receptor DC-SIGN to its prototypical ligands, fucose and the oligosaccharide Lewis-B, (Le ) in a dose-dependent way. Interestingly, such inhibition by HMOS and 2'-FL was not detected for another C-type lectin, langerin, which is evolutionarily similar to DC-SIGN. The cell-ligand competition assay using DC-SIGN expressing cells confirmed that 2'-FL inhibits the binding of DC-SIGN to Le . Molecular dynamic (MD) simulations show that 2'-FL exists in a preorganized bioactive conformation before binding to DC-SIGN and this conformation is retained after binding to DC-SIGN. Le has more flexible conformations and utilizes two binding modes, which operate one at a time via its two fucoses to bind to DC-SIGN. Our hypothesis is that 2'-FL may have a reduced entropic penalty due to its preorganized state, compared to Le , and it has a lower binding enthalpy, suggesting a better binding to DC-SIGN. Thus, due to the better binding to DC-SIGN, 2'-FL may replace Le from its binding pocket in DC-SIGN. The MD simulations also showed that 2'-FL does not bind to langerin. Our studies confirm 2'-FL as a specific ligand for DC-SIGN and suggest that 2'-FL can replace other DC-SIGN ligands from its binding pocket during the ligand-receptor interactions in possible immunomodulatory processes.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36499067</pmid><doi>10.3390/ijms232314745</doi><orcidid>https://orcid.org/0000-0001-9819-383X</orcidid><orcidid>https://orcid.org/0000-0001-8517-4904</orcidid><orcidid>https://orcid.org/0000-0003-3619-9982</orcidid><orcidid>https://orcid.org/0000-0002-8678-9182</orcidid><orcidid>https://orcid.org/0000-0003-4723-3584</orcidid><orcidid>https://orcid.org/0000-0002-6098-5281</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2022-11, Vol.23 (23), p.14745
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9737664
source MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Antigens
Binding
Breast milk
Carbohydrates
Competition
Conformation
DC-SIGN protein
Dendritic cells
Fucose - analysis
Humans
Hydrogen bonds
Immunomodulation
Lactose
Lectins, C-Type - metabolism
Ligands
Milk
Milk, Human - metabolism
Molecular dynamics
Oligosaccharides
Receptors, Cell Surface - metabolism
Simulation
Trisaccharides - pharmacology
title Human Milk Oligosaccharide 2'-Fucosyllactose Inhibits Ligand Binding to C-Type Lectin DC-SIGN but Not to Langerin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A47%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20Milk%20Oligosaccharide%202'-Fucosyllactose%20Inhibits%20Ligand%20Binding%20to%20C-Type%20Lectin%20DC-SIGN%20but%20Not%20to%20Langerin&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Mukherjee,%20Reshmi&rft.date=2022-11-25&rft.volume=23&rft.issue=23&rft.spage=14745&rft.pages=14745-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms232314745&rft_dat=%3Cproquest_pubme%3E2753302978%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2748550847&rft_id=info:pmid/36499067&rfr_iscdi=true